Cardiospecific Troponin Research Articles

Cardiospecific troponin T—the evaluation of its usefulness for staging the heart muscle's injury in the course of a high-dose epirubicin chemotherapy

Cardiospecific troponin T—the evaluation of its usefulness for staging the heart muscle's injury in the course of a high-dose epirubicin chemotherapy

Myocardial damage during percutaneous transluminal coronary angioplasty as evidenced by troponin T measurements

The present study was undertaken to assess the effect of balloon inflation during percutaneous transluminal coronary angioplasty on markers of myocardial damage. Seventy-five patients undergoing elective percutaneous transluminal coronary angioplasty were evaluated with serum creatine kinase MB and cardiospecific troponin T before and 1 and 4 days after the procedure. On day 1, 28% of the patients had increased cardiospecific troponin T values and 18% had increased creatine kinase MB values. On day 4, 24% had increased cardiospecific troponin T values, whereas all creatine kinase MB values were normal. A high degree of correlation between creatine kinase MB and cardiospecific troponin T on day 1, as well as between both markers on day 1 and cardiospecific troponin T on day 4 were found. The increased levels of cardiospecific troponin T on day 4 was significantly correlated with the total balloon inflation time (P < 0.001). We conclude that irreversible myocardial damage, as evidenced by increased cardiospecific troponin T values on day 4, occurs in an appreciable number of patients during percutaneous transluminal coronary angioplasty, and that this damage is strongly correlated with the total balloon inflation time.

Markers of myocardial injury in blood following PTCA: A comparison of CKMB, cardiospecific troponin T and troponin I

In 74 patients undergoing elective PTCA, CKMB, cTnT, cTnI-Access (cTnI-Acc) and cTnI-Abbott (cTnI-Abb) were measured in serum before and days 1 and 4 after the procedure. Two of the patients had pronounced biochemical evidence of AMI. In addition, a minor to moderate increase in CKMB, cTnT, cTnI-Acc and cTnI-Abb were found on day 1 in 13, 22, 18 and 25 patients, respectively. Excluding the two with AMI, cTnT was also increased on day 4 in 16 patients and cTnI-Abb in 15 patients, whereas CKMB and cTnI-Acc levels were essentially normal in all. Thus, an unexpected discrepancy between the two methods for cTnI was revealed on day 4. In these 16 patients, there was no statistically significant relationship between the level of cTnT on day 4 and the levels of CKMB or cTnI-Acc on day 1. This is in contrast to a significant correlation to cTnT and cTnI-Abb on day 1. Based on these results, it is speculated that the marker levels on day 1 are due to reversible as well as irreversible damage, whereas cTnT and TnI-Abb on day 4 more selectively reflect the degree of myocardial necrosis. cTnT and cTnI-Abb on day 4 are therefore proposed as valuable markers for further study of the clinical implications of myocardial damage following PTCA and related interventions.

Serum cardio-specific troponin T after open heart surgery in patients with and without perioperative myocardial infarction.

One hundred and sixteen consecutive patients undergoing open heart surgery were studied to evaluate the diagnostic use of cardiac specific troponin T in serum (S-TnT) measured preoperatively, at day 1 and day 4 postoperatively. The results were related to perioperative myocardial infarction (POMI), diagnostically based on ECG-changes, as well as to other perioperative variables. Cardiac surgery resulted in increased levels of S-TnT day 1 in all patients, and the level of this increase was dependent on the type of surgical procedure performed and the duration of cardiac perioperative ischaemia. Similar results were observed for serum creatine kinase isoenzyme (mass determination) (S-CKMB), but differences were generally less well correlated with other perioperative variables. At day 1, patients with POMI had higher levels of S-TnT as well as S-CKMB when compared to patients without POMI. At day 4, most patients still had elevated levels of S-TnT, but the difference in S-TnT levels between patients with POMI and patients without POMI was more pronounced. In contrast, the levels of S-CKMB were essentially normalized in both groups. Measurements of S-TnT at day 4 appears to be of significant value in diagnosing POMI. However, most of the patients without POMI had increased levels of S-TnT at day 4, suggesting that some irreversible operatively induced myocardial damage had occurred. Thus, even at a late postoperative stage the perioperative duration of ischaemia and type and extent of the surgical procedure should be taken into consideration.

Cardio specific Troponin I in patients with Aortic stenosis

To evaluate the association of Cardio specific Troponin I (CTnI) and aortic stenosis. Cross sectional study was conducted among 20 aortic stenosis patients and 20 control groups. A structured questioner and checklist was used to collect data through face to face interview, Echocardiography findings, and laboratory estimation of cTnl. A total 20 patients and 20 healthy control subjects were investigated for cTnl. cTnl level was within normal physiological limits in all the control subjects. The mean value was 0.02±00. The mean cTnl level in Aortic stenosis patients were 0.67±0.81. EJection fraction of Aortic stenosis patients were normal, indicating that cases yet not develops complication (eg; Heart failure). The cTnl in control group and Aortic stenosis patients shows significant difference of mean (p &lt; 0.001). cTnl level in Aortic stenosis patients increases in absence of heart failure indicating that it can expose cardiomyocyte injury prior to the development of over Left ventricular dysfunction. So that, serial monitoring of cTnl could help clinician to give definitive treatment before development of complications. Keywords: Cardiospecific Troporin I. Aortic Stenosis. doi: 10.3329/bjpath.v24i1.2875 Bangladesh J Pathol 24 (1) : 9-11

Cardio Specific Troponin-I in Patients with Valvular Heart Disease

Valvular heart disease is a common cardiac disease in our country. The valvular heart disease which we face in our day to day hospital and private practice is due to chronic sequlae of rheumatic fever. In chronic rheumatic heart disease mitral valve is affected in more than 90% of cases and aortic valve is the next most frequently affected valve. This study was done to evaluate the association of Cardio specific TroponinI I (cTnI) and valvular heart disease. Cross sectional study was conducted among 60 valvular heart disease patients and 30 control groups. A structured questioner and checklist was used to collect data through face to face interview, echocardiography findings and laboratory estimation of cTnI.A total 60 patients and 30 healthy control subjects were investigated for cTnI. cTnI level was within normal physiological limits in all the control subjects. The mean value was 0.02±00. The mean cTnI level in aortic stenosis patients was 0.67±0.81.In mitral stenosis patients and in patients with both aortic and mitral stenosis cTnI level was also within normal physiological limits. The mean level was 0.02±0.21 and 0.15±0.50 respectively. Ejection fraction of all the patients were normal, indicating that cases yet not developed complication (eg; Heart failure). The cTnI in control group and aortic stenosis patients shows significant difference of mean (&lt;0.001).But the cTnI in control group and other groups of patients shows no significant difference of mean (&gt;0.05) cTnI level in aortic stenosis patients increases in absence of heart failure indicating that it can expose cardiomyocyte injury prior to the development of overt Left ventricular dysfunction. So that, serial monitoring of cTnI could help clinicians to give definitive treatment before development of complications. Key words: Cardiospecific Troponin I; Aortic stenosis DOI: 10.3329/bjpp.v25i1.5737Bangladesh J Physiol Pharmacol 2009; 25(1&amp;2) : 4-6